Novo Nordisk’s new weight-loss drug helped patients lose even more weight on average than its current Wegovy blockbuster treatment, an early-stage trial showed, as the drugmaker races to develop the next generation of obesity medicines.

Novo Nordisk A/S’s next-generation obesity shot CagriSema helped patients lose weight in large studies despite only about three-quarters of the patients ever making it to the highest dose. Surprisingly,

Wegovy will be available in India in five strengths. While the lower doses (0.25 mg, 0.5 mg, and 1 mg) will be priced at ₹17,345 for a month (four weekly doses), the higher doses, 1.7 mg and 2.4 mg, will have price tags of ₹24,280 and ₹26,050, respectively, for a month’s treatment.